-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RYN/RTqODHNXSDbphVGwYBJ6zY4anPJZEGtZ3ioPpYCYkPonl7b4DjfUW344Pqrj SICK5Q5+l3qmqO0GeHdbFg== 0000950135-05-007064.txt : 20051221 0000950135-05-007064.hdr.sgml : 20051221 20051221140617 ACCESSION NUMBER: 0000950135-05-007064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051215 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20051221 DATE AS OF CHANGE: 20051221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31918 FILM NUMBER: 051278057 BUSINESS ADDRESS: STREET 1: 345 VASSAR STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6176795500 MAIL ADDRESS: STREET 1: 345 VASSAR STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 8-K 1 b58252ipe8vk.htm IDERA PHARMACEUTICALS, INC. FORM 8-K Idera Pharmaceuticals, Inc. Form 8-K
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2005
IDERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
         
Delaware
(State or Other Juris-
diction of Incorporation 		  001-31918
(Commission
File Number) 		  04-3072298
(IRS Employer
Identification No.)
     
345 Vassar Street,
Cambridge, Massachusetts
(Address of Principal Executive Offices) 		  02139
(Zip Code)
(617) 679-5500
Registrant’s telephone number, including area code:
n/a
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
  ¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 1.01.  Entry into a Material Definitive Agreement
     On December 15, 2005, the Compensation Committee of the Board of Directors of Idera Pharmaceuticals, Inc. (the “Company”) approved:
  Ÿ   annual base salaries for Sudhir Agrawal, the Company’s Chief Executive Officer and Chief Scientific Officer, and Robert G. Andersen, the Company’s Chief Financial Officer and Vice President of Operations; and
 
  Ÿ   the payment of cash bonus awards to Dr. Agrawal and Mr. Andersen for 2005.

                   
    2006 Annual Base Salary     2005 Bonus  
 
Sudhir Agrawal
     $445,000       $120,000  
 
Robert G. Andersen
     $313,500       $50,000  

 

 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  HYBRIDON, INC.
 		  
Date: December 21, 2005 By:   /s/ Robert G. Andersen    
    Robert G. Andersen   
    Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----